Jim Weiss is a senior corporate communications counselor with nearly 25 years of experience in strategic media and investor relations and marketing communications focused in the healthcare, medical device, biotechnology, pharmaceutical, and life sciences industries. Before starting his own firm, Jim was director of corporate communications and investor relations at medical device startup, Heartport, a pioneer in minimally invasive cardiac surgery. Prior to Heartport, Jim was director of worldwide product communications at Rhone-Poulenc Rorer Inc. (now Aventis) in its Paris headquarters where he led the public relations launches and programs for its leading products worldwide, including LOVENOX, TAXOTERE, Azmacort, Nasacort,
Synercid, Campto, and RILUTEK. Before that, he was at Genentech coordinating communications on behalf of its lead products in the early to mid-1990s: Activase for heart attack and stroke, human growth hormone, Pulmozyme for cystic fibrosis, and Herceptin for breast cancer.